Biotech: Page 29

  • A light blue puzzle depicting rows of workers has scattered pieces missing, showing a yellow background underneath.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    Moderna, Eli Lilly and Schrödinger seek to boost financial and people strategies with key new hires

    How the latest personnel shifts are impacting each company and the industry at large. 

    By Karissa Waddick • Aug. 24, 2022
  • Money pills
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Patents, pandemics and pricing: a peek at the top drug from every big pharma

    A look at how the biggest pharma companies in the world and their top-selling drugs fared in the first half of the year.

    By • Aug. 22, 2022
  • cancer R&D Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Oncology R&D

    Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

    By PharmaVoice staff
  • President Biden signs the Inflation Reduction Act surrounded by members of congress and backed by American flags in the White House.
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    3 ways pharma can prep for Biden’s sweeping drug pricing policies

    Now that Medicare will be able to negotiate drug prices under the Inflation Reduction Act, the industry can expect to see some changes. Here are some tips on how to navigate the changing tide.

    By Karissa Waddick • Aug. 18, 2022
  • Pill
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Inventing the COVID vax pill: a matter of convenience and durability

    Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

    By Kelly Bilodeau • Aug. 17, 2022
  • Nasal spray
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Right under our noses: Could COVID-19 vaccines be better as nasal spray?

    Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

    By Kelly Bilodeau • Aug. 16, 2022
  • A doctor and a businessperson shaking hands.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    As pharma M&A ramps up, U.S. execs are bullish on more deals

    What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.

    By • Aug. 11, 2022
  • cell therapy infusion
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    4 ways to nail the launch of your cell therapy

    A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.

    By • Aug. 10, 2022
  • A baby harp seal pup lays on ice in the White Sea.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

    With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

    By Alexandra Pecci • Aug. 9, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    How real world evidence is impacting rare disease drug development

    ICON’s Will Maier shares how a more patient-focused approach to trials is leading to alternatives for randomization.

    By Kim Ribbink • Aug. 9, 2022
  • CEO pay
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Are Big Pharma CEOs earning their pay?

    While compensation packages at the top may not always reflect value, it’s not necessarily an industrywide problem.

    By Kelly Bilodeau • Aug. 8, 2022
  • Heather Schwoebel head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Alloy Therapeutics’ Heather Schwoebel

    The CBO and COO is leaning on her experience navigating the unknown to turn Alloy into an innovation multiplier.

    By • Aug. 3, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Karissa Waddick • Aug. 3, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Taking probiotics where they’ve never gone before

    How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

    By Karissa Waddick • Aug. 2, 2022
  • Catherine Owen
    Image attribution tooltip

    Permission granted by Catherine Owen.

    Image attribution tooltip
    Q&A

    A glimpse inside Bristol Myers Squibb’s integration with Celgene

    Catherine Owen, senior vice president of major markets, discusses the hurdles — and successes — of bringing the two ‘powerhouses’ together.

    By • Aug. 1, 2022
  • Artifical intelligence
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Q&A

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By • July 27, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Democrats think they've found a balance between drug innovation and pricing negotiation

    A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

    By Karissa Waddick • July 26, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images
    Image attribution tooltip
    Q&A

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    By Kelly Bilodeau • July 25, 2022
  • Neuron
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

    The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

    By • July 25, 2022
  • newborn screening
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    The earlier the better: New consortium leverages infant screening to accelerate treatment

    Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

    By Kim Ribbink • July 25, 2022
  • A red Moderna sign hangs on the front of a beige building.
    Image attribution tooltip
    Maddie Meyer / Staff via Getty Images
    Image attribution tooltip

    Moderna's next vax target? A little-known cause of birth defects

    How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

    By Karissa Waddick • July 21, 2022
  • MeiMei Hu Headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Image attribution tooltip
    Podcast

    Woman of the Week: Vaxxinity's Mei Mei Hu

    Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.

    By • July 20, 2022
  • A person wearing a purple latex glove holds a petri dish with pink and red spots vertically with their thumb and index finger.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    By the numbers: The rising danger of superbugs

    A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

    By Karissa Waddick • July 20, 2022
  • R&D costs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Biotech R&D spending has skyrocketed, and so have opportunities for savings

    With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

    By • July 19, 2022
  • A person holds a magnet pointed at multi-colored wooden figures of people sitting on dark wood-grain table.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Making Moves

    Making moves: Agios, BeiGene, Biocom California and more announce new key hires

    The latest executive personnel changes from around the industry.

    By Karissa Waddick • July 18, 2022